Revance Therapeutics RVNC 深 滬
等待開盤 08-20 09:30:00 美东时间
3.65
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.65
- 總市值 3.80亿
- 52周最高 7.56
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.30
- 委 比 0.00%
- 總股本 1.04亿
- 歷史最高 42.41
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.30
- 每 手 1
- 風險率 1.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AEON Biopharma announces CEO appointment
AEON Biopharma (NYSE:AEON) announced the appointment of Rob Bancroft as president and chief executive officer, effective April 29, 2025. Bancroft will also join AEON’s board of directors. Prior to joi...
04-22 04:34
Crinetics Pharmaceuticals appoints Tobin Schilke as CFO
Crinetics Pharmaceuticals (NASDAQ:CRNX) on Monday announced the appointment of Tobin Schilke as chief financial officer (CFO), effective February 28, 2025. Prior to joining Crinetics, Schilke served ...
02-24 21:57
RVNC Lawsuit Alert! Class Action Against Revance Therapeutics, Inc.
Aclass actionlawsuit was filed against Revance Therapeutics, Inc. (...
02-21 19:59
Teoxane withdraws takeover offer for Revance Therapeutics
Teoxane withdrew its $3.60 a share offer for Revance Therapeutics after Crown Labs raised its offer to $3.65. Revance ticked lower by 0.3% in premarket trading. Teoxane said that committed financing i...
01-30 22:16
Dynavax Advances Board Refreshment Program
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 202...
01-27 19:00
Revance Therapeutics jumps after Teoxane offers $3.60 a share
Revance Therapeutics (NASDAQ:RVNC) soared 16% after Teoxane offered to purchase the company for $3.60 a share in cash, above Crown Therapeutics $3.10 a share deal. Teoxane, which beneficially owns 6....
01-06 22:50
美股大行评级 | 潜在涨幅265%！Humacyte获机构上调目标价至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1078254829883351040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Benchmark：维持Humacyte(HUMA)"买入"评级，目标价从15美元升至17美元</p> <p>• Evercore ISI集团：维持BridgeBio Pharma(BBIO)"跑赢大市"评级，目标价从45
2024-12-24 09:30
Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $3.1
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $6.66 to $3.1.
2024-12-10 21:09
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Th...
2024-12-09 21:30
Catalyst Watch: Goldman Sachs finance conference; Adobe, CostCo earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events ...
2024-12-07 04:00
